News & Updates
Filter by Specialty:
Fenofibrate staves off vision loss in diabetes
The antilipidemic drug fenofibrate averts or delays diabetic retinopathy (DR) in diabetes patients with early retinal changes in the LENS trial, potentially paving the way for the least invasive route of drug delivery in this population.
Fenofibrate staves off vision loss in diabetes
08 Aug 2024
Dolutegravir plus lamivudine suppresses HIV without HBV reactivation
The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.
Dolutegravir plus lamivudine suppresses HIV without HBV reactivation
07 Aug 2024
PT-led on par with rheumatologist triage of joint pain referrals
A triage led by a physiotherapist (PT) performs as reliably as a rheumatologist triage of referrals for joint pain, with significantly fewer patients with inflammatory arthritis (IA) needing an in-clinic visit, a recent study has shown.
PT-led on par with rheumatologist triage of joint pain referrals
07 Aug 2024
Gut microbiota may unlock new diagnostic and treatment strategies for autism
Gut microbiota biomarkers show >90 percent sensitivity and specificity in diagnosing autism spectrum disorder (ASD). Gut microbiome modulation with a novel synbiotic formula, SCM06, may alleviate anxiety symptoms in children with ASD, according to researchers from the Chinese University of Hong Kong (CUHK).
Gut microbiota may unlock new diagnostic and treatment strategies for autism
07 Aug 2024
Biosimilar DMARDs cost-effective vs leflunomide in RA patients after MTX failure
An economic evaluation study by the University of Hong Kong (HKU) found treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) to be cost-effective compared with leflunomide in patients with rheumatoid arthritis (RA) who failed initial treatment with methotrexate (MTX).
Biosimilar DMARDs cost-effective vs leflunomide in RA patients after MTX failure
07 Aug 2024
Cabozantinib and SBRT: Two feasible post-IO strategies in HCC
Liver cancer is a major cause of death globally and in Hong Kong. Both first- and second-line treatment of the disease have evolved considerably over recent years, following the approval of immune checkpoint inhibitors (ICIs). At present, over half of hepatocellular carcinoma (HCC) patients require second-line treatment, yet data on therapies administered after immunotherapy are lacking. This article summarizes locally reported findings on use of cabozantinib and stereotactic body radiotherapy (SBRT) in HCC patients who progressed on immunotherapy.